Last $0.02 USD
Change Today 0.00 / 0.00%
Volume 10.0K
MYMX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

mymetics corp (MYMX) Snapshot

Open
$0.02
Previous Close
$0.02
Day High
$0.02
Day Low
$0.02
52 Week High
01/7/14 - $0.09
52 Week Low
09/5/13 - $0.01
Market Cap
6.6M
Average Volume 10 Days
67.2K
EPS TTM
$0.0043
Shares Outstanding
303.8M
EX-Date
--
P/E TM
3.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYMETICS CORP (MYMX)

Related News

No related news articles were found.

mymetics corp (MYMX) Related Businessweek News

No Related Businessweek News Found

mymetics corp (MYMX) Details

Mymetics Corporation, a vaccine company, develops vaccines that focus on the mucosal layer as a first line of defense against viruses entering the blood stream. The company also develops virosomes as a vaccine delivery platform. Its product pipeline consists of five proprietary vaccines in development for the prevention and treatment of human immunodeficiency virus type 1, malaria, herpes simplex virus type I and II, respiratory syncytial virus, and intra-nasal influenza. The company was founded in 1990 and is based in Epalinges, Switzerland.

9 Employees
Last Reported Date: 08/14/14
Founded in 1990

mymetics corp (MYMX) Top Compensated Officers

Chief Executive Officer, President, Chief Ope...
Total Annual Compensation: €216.0K
Chief Scientific Officer
Total Annual Compensation: €216.0K
Compensation as of Fiscal Year 2013.

mymetics corp (MYMX) Key Developments

Mymetics Corporation and Imugene Partner to Develop Cancer Immunotherapy Vaccine Candidate

Mymetics Corporation has entered into an exclusive agreement with Imugene to manufacture and develop its cancer immunotherapy, HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015. Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.

Mymetics Signs Agreement to Manufacture Virosome Based HER-Vaxx Cancer Immunotherapy

Mymetics announced that it has signed an exclusive agreement with Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015. Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.

Mymetics Corporation Auditor Raises 'Going Concern' Doubt

Mymetics Corporation filed its 10-K on Mar 28, 2014 for the period ending Dec 31, 2013. In this report its auditor, Peterson Sullivan PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYMX:US $0.02 USD 0.00

MYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYMX.
View Industry Companies
 

Industry Analysis

MYMX

Industry Average

Valuation MYMX Industry Range
No financial data is available for MYMX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYMETICS CORP, please visit www.mymetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.